
Opinion|Videos|April 30, 2025
CHE Subtypes
Author(s)Raj Chovatiya, MD, PhD
An expert discusses how chronic hand eczema (CHE) presents in various clinical and etiologic subtypes, including irritant and allergic contact dermatitis, atopic hand eczema, and protein contact dermatitis, with clinical manifestations ranging from hyperkeratotic to vesicular forms.
Advertisement
Video content above is prompted by the following:
CHE Morphological and Etiological Subtypes
Key Themes:
- Etiologic subtypes: Its 4 main categories are irritant contact dermatitis (most common), allergic contact dermatitis, atopic hand eczema, and protein contact dermatitis.
- Clinical morphologies: Include hyperkeratotic, acute recurrent vesicular, nummular eczema, and pulpitis presentations, all with distinct characteristics.
- Overlapping presentations: Most patients have mixed etiologies and clinical features rather than single, pure forms.
Notable Insights:
Dr Chovatiya noted that "etiologic subtypes don't predict specific clinical subtypes and clinical subtypes don't specifically predict etiologic subtypes," highlighting the complex presentation of CHE.
Advertisement
Related to this article

Children receiving 50 nmol PVX108 increased their tolerated peanut dose 2.4-fold, with no treatment-related anaphylaxis in the phase 2 trial.

Ackerman and Bunick review 52-week AMETHYST data for litifilimab in refractory cutaneous lupus and make the case for dermatology-led CLE care.

Lawrence Eichenfield, MD, discusses phase 2 nemolizumab data in children aged 2 - 11 with atopic dermatitis, from caregiver-rated itch to sleep gains.

In this Q&A, Jennifer K. Priessnitz, MD, explains why FAERS reporting proportions should not drive biologic selection and what data are needed next.

At ACAAI 2026, Jennifer Priessnitz, MD presented data which found omalizumab had the highest anaphylaxis reporting proportion among 7 respiratory biologics.

Pooled, blinded week 12 data from the phase 2 RENEW trial showed FVC improvement in 8 of 24 patients with IPF and no treatment-related serious AEs.

Ankeet Bhatt, MD, MBA, ScM, explains how prediction markets could threaten clinical trial integrity by undermining participant retention and trust.
Advertisement
Advertisement
Trending on HCPLive
1
Single Annual Injection Produces Significant and Sustained Lp(a) Reductions
2
Ruvonoflast Reduces hsCRP, Inflammation, CVD Risk With Downstream Effects
3
Lessons From ZEUS on Targeting Inflammation, With Peter Libby, MD
4
SUMMIT Substudy Reveals Tirzepatide’s Impact on LV, Atrial Metrics of HFpEF
5

